The new direct oral anticoagulants such us rivaroxaban, could play an important role in the anticoagulant treatment of patients with paroxysmal nocturnal hemoglobinuria where anticoagulant treatment is complex to run, since they have shown a reduction in serious bleeding complications compared to antithrombotic therapy with classical vitamin k antagonist.
Keywords: Anticoagulant therapy; bleeding complication; paroxysmal nocturnal hemoglobinuria; rivaroxaban; thrombosis.